SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura.
作者信息
Shah Hridaya, Kim Ann, Sukumar Senthil, Mazepa Marshall, Kohli Ruhail, Braunstein Evan M, Brodsky Robert A, Cataland Spero, Chaturvedi Shruti
机构信息
Johns Hopkins University School of Medicine, Baltimore, MD.
Department of Medicine, Johns Hopkins University, Baltimore, MD.
出版信息
Blood. 2022 Apr 21;139(16):2570-2573. doi: 10.1182/blood.2022015545.
Abstract
摘要
相似文献
1
SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura.严重急性呼吸综合征冠状病毒2型疫苗接种与免疫性血栓性血小板减少性紫癜
Blood. 2022 Apr 21;139(16):2570-2573. doi: 10.1182/blood.2022015545.
2
Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients.米兰血栓性血小板减少性紫癜患者队列中接种SARS-CoV-2疫苗后的复发风险。
Haematologica. 2023 Nov 1;108(11):3152-3155. doi: 10.3324/haematol.2022.282478.
3
Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine.获得性血栓性血小板减少性紫癜：一种与 BNT162b2 疫苗相关的罕见疾病。
J Thromb Haemost. 2021 Sep;19(9):2314-2317. doi: 10.1111/jth.15420. Epub 2021 Jul 7.
4
Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection.COVID-19 疫苗接种和/或同时 COVID-19 感染可能引发免疫性血栓性血小板减少性紫癜（iTTP）复发。
BMJ Case Rep. 2022 Jul 28;15(7):e247524. doi: 10.1136/bcr-2021-247524.
5
Hemostatic Profile and Serological Response of Patients with Immune Thrombotic Thrombocytopenic Purpura after Receiving BNT162b2 Vaccine: A Prospective Study.免疫性血栓性血小板减少性紫癜患者接受 BNT162b2 疫苗后的止血谱和血清学反应：一项前瞻性研究。
Thromb Haemost. 2023 Oct;123(10):945-954. doi: 10.1055/s-0043-1768921. Epub 2023 May 12.
6
Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination.新型冠状病毒肺炎疫苗接种后免疫介导的血栓性血小板减少性紫癜
Blood. 2022 Apr 21;139(16):2565-2569. doi: 10.1182/blood.2021015149.
7
Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases.接种 COVID-19 疫苗后的血栓性血小板减少性紫癜（TTP）：已报告病例的系统评价。
Thromb Res. 2022 Jun;214:115-121. doi: 10.1016/j.thromres.2022.04.020. Epub 2022 May 2.
8
Covid-19 vaccination in patients with immune-mediated thrombotic thrombocytopenic purpura: a single-referral center experience.免疫性血小板减少性紫癜患者的新冠病毒疫苗接种：单转诊中心经验
Haematologica. 2023 Jul 1;108(7):1957-1959. doi: 10.3324/haematol.2022.282311.
9
Unilateral linear purpuric rash heralding SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia.单侧线性紫癜性皮疹预示着新型冠状病毒2型疫苗诱导的免疫性血栓性血小板减少症。
J Eur Acad Dermatol Venereol. 2022 Jun;36(6):e429-e431. doi: 10.1111/jdv.18014. Epub 2022 Feb 23.
10
Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine.血栓性血小板减少性紫癜：COVID-19 bnt162b2 疫苗接种后的新威胁
Int J Hematol. 2021 Nov;114(5):626-629. doi: 10.1007/s12185-021-03190-y. Epub 2021 Jul 15.
引用本文的文献
1
Immune Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, Therapy and Open Issues.免疫性血栓性血小板减少性紫癜：病理生理学、诊断、治疗及未解决的问题。
Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024060. doi: 10.4084/MJHID.2024.060. eCollection 2024.
2
Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus.新型冠状病毒肺炎中血管内皮激活、高凝和血栓形成的机制：与糖尿病的关联。
Cardiovasc Diabetol. 2024 Feb 20;23(1):75. doi: 10.1186/s12933-023-02097-8.
3
Thrombocytopenic thrombotic purpura related to COVID-19 vaccine: apropos of 4 cases.与新冠疫苗相关的血小板减少性血栓性紫癜：附4例报告
Hematol Transfus Cell Ther. 2024 Oct-Dec;46(4):511-515. doi: 10.1016/j.htct.2023.11.008. Epub 2023 Dec 30.
4
Molecular Mimicry of the Viral Spike in the SARS-CoV-2 Vaccine Possibly Triggers Transient Dysregulation of ACE2, Leading to Vascular and Coagulation Dysfunction Similar to SARS-CoV-2 Infection.SARS-CoV-2 疫苗中病毒刺突的分子模拟可能会导致 ACE2 短暂失调，导致类似于 SARS-CoV-2 感染的血管和凝血功能障碍。
Viruses. 2023 Apr 25;15(5):1045. doi: 10.3390/v15051045.
5
Pitfalls of Thrombotic Microangiopathies in Children: Two Case Reports and Literature Review.儿童血栓性微血管病的陷阱：两例病例报告及文献综述
Diagnostics (Basel). 2023 Mar 24;13(7):1228. doi: 10.3390/diagnostics13071228.
6
Adverse Hematological Effects of COVID-19 Vaccination and Pathomechanisms of Low Acquired Immunity in Patients with Hematological Malignancies.新型冠状病毒肺炎疫苗接种的不良血液学效应及血液系统恶性肿瘤患者获得性免疫低下的发病机制
Vaccines (Basel). 2023 Mar 15;11(3):662. doi: 10.3390/vaccines11030662.
7
Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients.米兰血栓性血小板减少性紫癜患者队列中接种SARS-CoV-2疫苗后的复发风险。
Haematologica. 2023 Nov 1;108(11):3152-3155. doi: 10.3324/haematol.2022.282478.
8
Hematological Questions in Personalized Management of COVID-19 Vaccination.新型冠状病毒肺炎疫苗个性化管理中的血液学问题
J Pers Med. 2023 Jan 30;13(2):259. doi: 10.3390/jpm13020259.
9
[Chinese consensus on severe acute respiratory syndrome coronavirus-2 vaccination in adult patients with hematological diseases (2023)].《成人血液病患者新型冠状病毒2型疫苗接种中国专家共识（2023年版）》
Zhonghua Xue Ye Xue Za Zhi. 2023 Jan 14;44(1):19-25. doi: 10.3760/cma.j.issn.0253-2727.2023.01.004.
10
Covid-19 vaccination in patients with immune-mediated thrombotic thrombocytopenic purpura: a single-referral center experience.免疫性血小板减少性紫癜患者的新冠病毒疫苗接种：单转诊中心经验
Haematologica. 2023 Jul 1;108(7):1957-1959. doi: 10.3324/haematol.2022.282311.
本文引用的文献
1
Acquired thrombotic thrombocytopenic purpura following Pfizer COVID-19 vaccination.辉瑞新冠疫苗接种后获得性血栓性血小板减少性紫癜
EJHaem. 2021 Nov 16;3(1):207-210. doi: 10.1002/jha2.342. eCollection 2022 Feb.
2
Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine.接种 ChAdOx1 nCoV-19 疫苗后发生血栓性血小板减少性紫癜。
BMJ Case Rep. 2021 Oct 8;14(10):e246049. doi: 10.1136/bcr-2021-246049.
3
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP.新型冠状病毒疫苗接种与新发或原有特发性血小板减少性紫癜患者的 ITP。
Blood. 2022 Mar 10;139(10):1564-1574. doi: 10.1182/blood.2021013411.
4
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.腺病毒载体新冠疫苗诱导的免疫性血栓性血小板减少症的相关认识。
Blood. 2021 Dec 2;138(22):2256-2268. doi: 10.1182/blood.2021013231.
5
Recurrence of Thrombotic Thrombocytopenic Purpura after mRNA-1273 COVID-19 Vaccine Administered Shortly after COVID-19.新冠病毒感染后不久接种mRNA-1273新冠疫苗后血栓性血小板减少性紫癜复发
Case Rep Hematol. 2021 Sep 13;2021:4130138. doi: 10.1155/2021/4130138. eCollection 2021.
6
Vaccinations and Autoimmune Diseases.疫苗接种与自身免疫性疾病
Vaccines (Basel). 2021 Jul 22;9(8):815. doi: 10.3390/vaccines9080815.
7
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine.首次接种BNT162b2 mRNA新冠疫苗后发生获得性血栓性血小板减少性紫癜。
Ann Hematol. 2022 Mar;101(3):717-719. doi: 10.1007/s00277-021-04584-y. Epub 2021 Jul 26.
8
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.苏格兰首剂 ChAdOx1 和 BNT162b2 COVID-19 疫苗与血小板减少性、血栓栓塞性和出血性事件。
Nat Med. 2021 Jul;27(7):1290-1297. doi: 10.1038/s41591-021-01408-4. Epub 2021 Jun 9.
9
First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination.首例与基于 mRNA 的抗 COVID-19 疫苗接种相关的新发免疫性血小板减少性紫癜（iTTP）发作。
J Thromb Haemost. 2021 Aug;19(8):2014-2018. doi: 10.1111/jth.15418. Epub 2021 Jul 5.
10
Exacerbation of immune thrombocytopenia following COVID-19 vaccination.接种 COVID-19 疫苗后免疫性血小板减少症恶化。
Br J Haematol. 2021 Nov;195(3):365-370. doi: 10.1111/bjh.17645. Epub 2021 Jun 24.
Zotero 插件